ACM
CCCC icon

Aster Capital Management’s C4 Therapeutics CCCC Stock Holding History

Aster Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-77,734
Closed -$111K – 1008
2025
Q2 		$111K Buy
+77,734
New +$113K 0.03% 495

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aster Capital Management's CCCC Position: Q3 2025 in Review

Aster Capital Management sold out of C4 Therapeutics (CCCC) in Q3 2025, closing a stake of 77,734 shares — an estimated $111K sold.

Aster Capital Management first reported a position in CCCC in Q2 2025 and held it in 1 quarter. The position peaked at $111K in Q2 2025. 97 funds tracked by Wall St. Rank hold CCCC as of Q3 2025.

  • Aster Capital Management reported no remaining C4 Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Aster Capital Management sold 77,734 C4 Therapeutics shares in Q3 2025, an estimated $111K.
  • Aster Capital Management first reported a position in C4 Therapeutics in Q2 2025 and held it in 1 quarter.
  • Aster Capital Management's C4 Therapeutics position peaked at $111K in Q2 2025.
  • 97 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2025.

Based on Aster Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.